Tandem Diabetes Care Stock News

Analysts expect that Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will announce $0.20 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Tandem Diabetes Cares earnings. The lowest EPS estimate is $0.16 and the highest is $0.27. Tandem Diabetes Care posted earnings per share of $0.24 []

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Analysts predict that Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will announce sales of $197.97 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Tandem Diabetes Cares earnings. The lowest sales estimate is $196.47 million and the highest is $201.10 million. Tandem Diabetes Care posted sales of $168.07 million in the []

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

Tandem Diabetes Care (NASDAQ:TNDM) had its target price upped by investment analysts at Piper Sandler from $140.00 to $150.00 in a report issued on Monday, The Fly reports. The firm currently has an overweight rating on the medical device companys stock. Piper Sandlers price target indicates a potential upside of 14.50% from the stocks current []

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Automated insulin delivery technology developer Tandem Diabetes Care (NSDQ:TNDM) announced that it made new appointments in three executive leadership positions. San Diego-based Tandem named Rick Carpenter as CTO, Libba Sapitsky as SVP of Customer Care and Rizwan Pervez as SVP of Quality and Regulatory. According to a news release, Carpenter, a veteran of more than [] The post Tandem Diabetes Care expands leadership team appeared first on Drug Delivery Business .

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) SVP James Leal sold 1,905 shares of Tandem Diabetes Care stock in a transaction on Monday, November 29th. The stock was sold at an average price of $130.96, for a total transaction of $249,478.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through []

LAS VEGAS , Dec. 1, 2021 /PRNewswire/ -- DelveInsight''s Insulin Delivery Devices Market Insights and Forecast report provides the current and forecast Insulin Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Insulin Delivery Devices Market. Some of the salient features from the Insulin Delivery Devices Market report: As per DelveInsight analysis, in terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes. Major pharma players working proactively in the Insulin Delivery Devices Market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean ( Hangzhou ) Medical Technology Co Ltd, Owen Mumford , SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

During the last session, Tandem Diabetes Care Inc. (NASDAQ:TNDM)s traded shares were 0.3 million, with the beta value of the company hitting 0.33. At the end of the trading day, the stocks price was $129.66, reflecting an intraday loss of -2.42% or -$3.22. The 52-week high for the TNDM share is $143.67, that puts it Tandem Diabetes Care Inc. (NASDAQ: TNDM) Continues To Thrive In 2021, As Its Stock Is Up 35.51% Year-To-Date Read More »

Tributary Capital Management LLC bought a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 15,900 shares of the medical device companys stock, valued at approximately $1,898,000. Other large investors also recently bought and sold shares of the company. Tocqueville Asset Management L.P. increased its stake []

Bank of America Corp DE grew its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 16.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,771 shares of the medical device companys stock after purchasing an additional 14,572 shares during the []

Louisiana State Employees Retirement System bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 16,100 shares of the medical device companys stock, valued at approximately $1,922,000. Several other large investors also []

These companies have a history of crushing the market.

These companies have a history of crushing the market.